Are Peptides Worth It? An Honest Evidence-Based Ranking

Of the 15+ peptides marketed for performance and longevity, only three have evidence strong enough to justify the cost-risk trade-off.

The rest fall into one of two camps: promising preclinical work that hasn't replicated in humans, or popular biohacker stack items with marketing far ahead of data.

This is the honest ranking. Useful even — or especially — if you're already running peptides and want to know whether your protocol is evidence-based or vibes-based.

If you haven't read What are peptides? A clinical primer, start there. This post assumes you understand the categories.

Before any specific peptide, four questions to ask:

1. Is there a Phase 3 randomized controlled trial in humans? This is the gold standard.
2. Is the safety profile understood at proposed dosing? Or is "we don't know what happens at year 5" the honest answer?
3. What is the regulatory status? FDA approved? Compounding pharmacy available? Or research-grade gray market?
4. What's the cost relative to alternatives that produce similar outcomes through proven means?

Most peptides fail at least one of these questions. The three that pass all four are the ones worth considering.

Brand names: Ozempic / Wegovy (semaglutide), Mounjaro / Zepbound (tirzepatide).

Evidence level: Strongest of any peptide on this list. Multiple Phase 3 RCTs with tens of thousands of participants. FDA-approved. Insurance-covered for specific indications.

What they do: Activate the GLP-1 receptor (and GIP receptor for tirzepatide), producing significant weight loss, blood sugar normalization, reduced appetite, and improved cardiovascular outcomes. The STEP-1 trial showed ~15% body weight reduction in obesity over 68 weeks.¹ The SURMOUNT-1 trial for tirzepatide showed ~22% body weight reduction at higher doses.²

Who they're for:

• Diagnosed Type 2 diabetes
• Obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with comorbidities
• Possibly cardiovascular risk reduction in specific populations³

Who they're NOT for:

• Cosmetic weight loss in people with BMI < 27
• People with personal/family history of medullary thyroid cancer (boxed warning)
• During pregnancy
• "Just to lose 10 pounds" without metabolic indication

Side effects: GI side effects (nausea, vomiting, constipation) are common, often subside. Gallbladder issues. Muscle loss alongside fat loss (requires resistance training to mitigate). Documented rebound weight regain if discontinued without lifestyle changes.

Cost: $900-1500/month without insurance. With insurance for indicated patients, often $25-50/month copay.

KINS position: these are real medications, not biohacks. Used for indicated patients, they work. Used inappropriately for cosmetic weight loss in lean individuals, they have meaningful downside risks that outweigh benefits.

Brand name: Egrifta (specific FDA-approved formulation).

Evidence level: FDA-approved for HIV-associated lipodystrophy since 2010. Multiple Phase 3 RCTs in that indication.⁴ Off-label use for general body composition in healthy adults has less research but is mechanistically plausible.

What it does: Stimulates the pituitary to release endogenous growth hormone, leading to increased IGF-1, reduced visceral fat, and improved body composition.⁵

Who it's for (FDA-indicated): Adults with HIV-associated lipodystrophy.

Who it might be useful for (off-label, with physician oversight): Adults with elevated visceral adipose tissue and confirmed GH-axis dysfunction. Athletes recovering from injury (mixed evidence). Specific clinical pictures only — not general "anti-aging."

Side effects: Injection-site reactions. Potential effect on insulin sensitivity. Joint pain (likely from elevated IGF-1).

Cost: $1500-3000/month for branded Egrifta. Substantially less through compounded sermorelin (similar mechanism, different molecule, available through specialty pharmacies).

KINS position: Tesamorelin is real medicine with real indications. Off-label use in lean, healthy adults for "longevity" is less validated. If you're considering it, work with an endocrinologist who can run proper baseline testing.

Evidence level: Substantial preclinical (animal) research. Promising mechanism. Almost no human RCTs of meaningful size.⁶

What it does (in animal models): Accelerates tissue healing — tendon, ligament, GI tract. Reduces inflammation locally. Promotes angiogenesis.

Why it's on this list despite weak human data:

• The mechanism is plausible
• Preclinical evidence is consistent across multiple labs and models
• Real-world use among athletes is extensive (uncontrolled but informative)
• Oral formulations (vs. injection) have reasonable safety profile

Why it's at #3 with major caveats:

• The 2023 FDA crackdown removed it from legitimate compounding pharmacy availability
• Research-grade vendor supply chain is regulatory gray zone
• Long-term safety in humans is genuinely unknown
• Almost zero placebo-controlled human research

KINS position: If you have a specific tissue-healing application (post-injury, post-surgery, chronic GI issues), and you can source from a quality vendor, and you work with a clinician who's familiar — BPC-157 has a plausible case. But the evidence base is weaker than the marketing suggests, and the regulatory situation in the US is unfavorable.

We don't include BPC-157 in default KINS protocols. We have case-by-case conversations when guests bring it up.

Marketed combination for GH release. Popular biohacker stack. Has plausible mechanism. Lacks large human RCTs. Lost compounding eligibility in 2023.

What people are doing: ordering through research-grade vendors. Quality varies wildly. The combination doesn't have published evidence supporting its specific claims at the doses used.

If you want GH-axis support: tesamorelin or sermorelin via proper channels are the validated options.

Marketed for athletic recovery. Almost no human research. Animal data only. Lost compounding eligibility 2023.

The case for TB-500 is theoretical. The case against: no peer-reviewed human RCT showing the claimed effects.

Russian-developed cognitive peptides with real research — but most of it published in Russian journals and not validated by Western standards.

Cerebrolysin has some FDA orphan drug status for specific stroke indications. Selank and Semax don't.

If you're outside the US and have a reasonable clinician overseeing it: case-by-case basis. In the US: limited legal access, limited safety data, limited oversight.

Marketed for longevity / telomere extension. Almost entirely based on the work of Vladimir Khavinson (Russia, 1990s-present). Few independent replications. Lost compounding eligibility 2023.

The longevity claims are dramatic. The evidence base for them in humans is thin.

Marketed for sleep. Inconsistent evidence across small studies. Not currently a credible sleep intervention compared to behavioral interventions (sleep architecture work, evening light protocols, etc.).

GHK-Cu, Argireline, Matrixyl: real topical effects on skin. Systemic injection for "anti-aging" much less validated.

For skincare: useful. As a longevity intervention: oversold.

A common biohacker move: take BPC-157 + TB-500 + CJC-1295 + Ipamorelin + Epitalon simultaneously.

The problems:

• You can't tell what's working. If something improves, you don't know which compound caused it. If something goes wrong, you don't know which to stop.
• Interactions are unstudied. None of these have been tested in combination. Mechanisms overlap; effects may not be additive.
• Safety compounds risk. Each peptide has individual side-effect profiles. Combined, the risk surface grows.
• It's expensive. $500-1000/month for a stack with limited evidence per component.

The cleaner approach: pick the one or two peptides with the best evidence for your specific goal. Run them long enough to assess. Adjust.

Specific scenarios where peptides have a real case:

You have a specific clinical indication — diabetes, obesity with comorbidity, HIV-associated lipodystrophy, severe injury requiring tissue healing.

You've optimized the fundamentals first — sleep, nutrition, exercise, stress regulation. Peptides are layer N, not layer 1.

You're working with a physician who knows this space — not a wellness clinic that prescribes the same stack to every patient.

You can verify supply chain quality — for compounded peptides, that means a licensed specialty pharmacy. For OTC supplements (like Tru Niagen for NAD), that means third-party tested products from established companies.

You're willing to test outcomes — bloodwork before, bloodwork after, retest at 3-6 months. Without measurement, you don't know if it's working.

Honest limits:

• It doesn't include specific dosing. Individual to person, peptide, and clinical context.
• It doesn't recommend specific vendors. The supply chain is too variable, the legal landscape too fluid.
• It doesn't substitute for a clinician's evaluation. If you're considering peptides, work with someone who knows this space.
• The evidence base will change. Trials are ongoing for some of these. Check current literature when you actually act on this.

Should I take BPC-157 for my injury?
Talk to a sports medicine or orthopedic doctor first. PT, NSAIDs, and time work for most injuries. BPC-157 might help; the evidence is limited; the supply chain is unfavorable.

Is GLP-1 RA safe for someone with normal BMI?
The risk/benefit calculation changes when there's no metabolic indication. Muscle loss, GI effects, and rebound risk loom larger when you don't have weight to lose. Not recommended for cosmetic use in lean individuals.

Can I get tesamorelin without HIV?
Off-label prescribing happens. Find an endocrinologist who specializes in growth hormone therapies. Requires baseline workup including IGF-1.

Are research-grade peptides "fake"?
Sometimes. Mass spectrometry testing of consumer-purchased "research-grade" peptides has found products that don't contain what they claim, contain contaminants, or have wildly variable concentrations. Buyer beware.

Will peptides make me lose hair / cause cancer / damage my organs?
Peptide-specific. GH-axis peptides can affect insulin sensitivity. GLP-1 RAs have specific contraindications. BPC-157 long-term safety is unknown. Each has its own profile.

Should I do peptides instead of TRT / HRT?
Different mechanisms, different applications. TRT/HRT replace declining hormones directly. Peptides like sermorelin/tesamorelin trigger your own production. Talk to an endocrinologist — these are different decisions.

This is the evidence-based version. Three peptides justify the cost-risk trade-off; most don't. The marketing has run ahead of the science in most cases.

It's not anti-peptide. GLP-1 RAs and tesamorelin (in their proper indications) are clinical wins.

It's not a list of products to buy. It's a framework for evaluating the next peptide claim you see on Twitter or hear at a longevity conference.

If you're going to do peptides: pick the ones with evidence, work with a clinician who knows the space, verify your supply chain, measure outcomes. Don't stack speculatively. Don't chase trends. The hype cycle in this space turns over fast.

— Cathy

Up next:

What are peptides? Clinical primer — if you need the foundational explainer.

Bloodwork panel every high-achiever should run — what to test before any peptide protocol.

The 14-Day Deep Reset →

1. Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. PubMed
2. Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. PubMed
3. Marso SP, et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844. PubMed
4. Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370. PubMed
5. Stanley TL, et al. (2014). Effects of long-term tesamorelin treatment on visceral adipose tissue and metabolic parameters in HIV-infected patients. AIDS, 28(15), 2287-2295. PubMed
6. Sikiric P, et al. (2010). Stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design, 16(10), 1224-1234. PubMed
7. Chang CH, et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11), 19066-19077. PubMed
8. Müller TD, et al. (2022). Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery, 21(3), 201-223. PubMed
9. FDA Compounding Quality Center of Excellence. (2023). Bulk drug substances nominated for use in compounding under section 503A. FDA